Medical Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
Medical Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
J Immunother Cancer. 2020 Jul;8(2). doi: 10.1136/jitc-2020-000952.
Pneumonitis is a rare but serious adverse event caused by cancer immunotherapy. The diagnosis between COVID-19-induced pneumonia and immunotherapy-induced pneumonitis may be challenging in the era of COVID-19 outbreak. Some clinical symptoms and radiological findings of pneumonitis can be attributed to the coronavirus infection as well as to an immune-related adverse event. Identifying the exact cause of a pneumonitis in patients on treatment with immunotherapy is crucial to promptly start the most appropriate treatment. The proper management of immune checkpoint inhibitors for the risk of pneumonia must take into account a series of parameters. Accurate attention should be payed to symptoms like cough, fever and dyspnea during immunotherapy.
肺炎是癌症免疫疗法引起的罕见但严重的不良事件。在 COVID-19 爆发时期，COVID-19 引起的肺炎和免疫疗法引起的肺炎之间的诊断可能具有挑战性。肺炎的一些临床症状和影像学发现既可以归因于冠状病毒感染，也可以归因于免疫相关的不良事件。在接受免疫治疗的患者中，确定肺炎的确切病因对于及时开始最恰当的治疗至关重要。对于肺炎风险的免疫检查点抑制剂的合理管理必须考虑一系列参数。在免疫治疗期间，应准确注意咳嗽、发热和呼吸困难等症状。
